X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9959) 9959
Magazine Article (32) 32
Newsletter (6) 6
Book Chapter (5) 5
Web Resource (3) 3
Book Review (2) 2
Dissertation (2) 2
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9033) 9033
male (5827) 5827
piperazines - therapeutic use (5357) 5357
piperazines - adverse effects (5135) 5135
female (4356) 4356
middle aged (3778) 3778
adult (3526) 3526
aged (2414) 2414
piperazines - administration & dosage (2386) 2386
imatinib mesylate (2160) 2160
treatment outcome (2100) 2100
pharmacology & pharmacy (1875) 1875
piperazines - pharmacology (1850) 1850
sildenafil citrate (1788) 1788
benzamides (1748) 1748
animals (1476) 1476
psychiatry (1432) 1432
pyrimidines - therapeutic use (1400) 1400
pyrimidines - adverse effects (1319) 1319
oncology (1286) 1286
antipsychotic agents - adverse effects (1181) 1181
antipsychotic agents - therapeutic use (1118) 1118
aripiprazole (1067) 1067
antineoplastic agents - therapeutic use (1064) 1064
double-blind method (1063) 1063
adolescent (1056) 1056
dose-response relationship, drug (1051) 1051
purines (965) 965
sulfones (965) 965
antineoplastic agents - adverse effects (935) 935
drug therapy (920) 920
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (910) 910
erectile dysfunction - drug therapy (887) 887
sildenafil (866) 866
double-blind (853) 853
hematology (815) 815
efficacy (776) 776
quinolones - therapeutic use (765) 765
schizophrenia - drug therapy (748) 748
quinolones - adverse effects (731) 731
care and treatment (727) 727
schizophrenia (714) 714
time factors (707) 707
piperazines - pharmacokinetics (704) 704
imatinib (694) 694
young adult (678) 678
drug therapy, combination (669) 669
clinical trials as topic (663) 663
pyrimidines - administration & dosage (651) 651
therapy (643) 643
neurosciences (638) 638
safety (617) 617
research (613) 613
medicine & public health (610) 610
erectile dysfunction (590) 590
phosphodiesterase inhibitors - therapeutic use (590) 590
aged, 80 and over (588) 588
medicine, general & internal (582) 582
clinical neurology (581) 581
rats (566) 566
thiazoles - therapeutic use (557) 557
sulfones - therapeutic use (554) 554
risk factors (552) 552
drug administration schedule (542) 542
analysis (541) 541
thiazoles - adverse effects (526) 526
cancer (524) 524
phosphodiesterase inhibitors - adverse effects (521) 521
administration, oral (509) 509
protein kinase inhibitors - therapeutic use (507) 507
chronic myelogenous leukemia (506) 506
urology & nephrology (502) 502
prasugrel hydrochloride (498) 498
drug interactions (497) 497
follow-up studies (492) 492
mice (473) 473
cardiac & cardiovascular systems (467) 467
purines - therapeutic use (458) 458
abridged index medicus (456) 456
chronic myeloid-leukemia (452) 452
prospective studies (426) 426
clinical trials (422) 422
protein kinase inhibitors - adverse effects (412) 412
antineoplastic agents - administration & dosage (409) 409
dosage and administration (408) 408
child (405) 405
chronic myeloid leukemia (402) 402
health aspects (401) 401
sulfones - adverse effects (401) 401
randomized controlled trials as topic (395) 395
vasodilator agents - therapeutic use (384) 384
protein-tyrosine kinases - antagonists & inhibitors (382) 382
impotence (380) 380
internal medicine (378) 378
antipsychotic agents - administration & dosage (373) 373
pharmacokinetics (373) 373
ticlopidine - analogs & derivatives (369) 369
psychiatric status rating scales (356) 356
retrospective studies (332) 332
olanzapine (330) 330
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9387) 9387
German (188) 188
French (139) 139
Japanese (129) 129
Chinese (68) 68
Spanish (62) 62
Russian (38) 38
Dutch (23) 23
Italian (22) 22
Hungarian (20) 20
Danish (16) 16
Polish (16) 16
Portuguese (14) 14
Norwegian (13) 13
Swedish (12) 12
Czech (5) 5
Hebrew (5) 5
Finnish (4) 4
Romanian (4) 4
Bulgarian (3) 3
Turkish (2) 2
Croatian (1) 1
Lithuanian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2008, Volume 58, Issue 4, pp. 545 - 570
Chemotherapeutic agents give rise to numerous well described adverse effects that may affect the skin, hair, mucous membranes, or nails... 
Dermatology | CELL LUNG-CANCER | CHRONIC MYELOGENOUS LEUKEMIA | GROWTH-FACTOR RECEPTOR | PEGYLATED LIPOSOMAL DOXORUBICIN | PHASE-II TRIAL | RADIATION-RECALL DERMATITIS | CHRONIC LYMPHOCYTIC-LEUKEMIA | TYROSINE-KINASE INHIBITOR | CHRONIC MYELOID-LEUKEMIA | HAND-FOOT SYNDROME | DERMATOLOGY | Erlotinib Hydrochloride | Niacinamide - analogs & derivatives | Drug Eruptions - pathology | Humans | Antibodies, Monoclonal - adverse effects | Phenylurea Compounds | Protein Kinase Inhibitors - adverse effects | Benzenesulfonates - adverse effects | Antibodies, Monoclonal, Humanized | Pyridines - adverse effects | Fusion Proteins, bcr-abl | Antineoplastic Agents - adverse effects | Nail Diseases - chemically induced | Drug-Related Side Effects and Adverse Reactions | Hair Diseases - chemically induced | Pyrroles - adverse effects | Mucous Membrane - drug effects | Cetuximab | Taxoids - adverse effects | Platinum Compounds - adverse effects | Drug Eruptions - etiology | Skin Diseases - chemically induced | Imatinib Mesylate | Piperazines - adverse effects | Antimetabolites - adverse effects | Indoles - adverse effects | Signal Transduction - drug effects | Pyrimidines - adverse effects | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Benzamides | Proteasome Inhibitors | Skin - drug effects | Protein-Tyrosine Kinases - antagonists & inhibitors | Chemotherapy | Platelet-derived growth factor | Formulae, receipts, prescriptions | Dermatologic agents | Lung cancer, Non-small cell | Cancer | Index Medicus
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 07/2016, Volume 134, Issue 3, pp. 248 - 261
.... In addition to familiarity with the dosing and monitoring of vitamin K antagonists, clinicians are accustomed to using vitamin K if there is a need to reverse the anticoagulant effect of vitamin K antagonists... 
anticoagulants | atrial fibrillation | venous thromboembolism | hemorrhage | CARDIAC & CARDIOVASCULAR SYSTEMS | ACTIVATED FACTOR-VII | ATRIAL-FIBRILLATION | IN-VITRO | THROMBIN GENERATION | DABIGATRAN ETEXILATE | PROTHROMBIN COMPLEX CONCENTRATE | SYMPTOMATIC VENOUS THROMBOEMBOLISM | PRACTICAL MANAGEMENT | PERIPHERAL VASCULAR DISEASE | STAGE RENAL-DISEASE | FACTOR XA INHIBITOR | Recombinant Proteins - therapeutic use | Plasma | Dabigatran - adverse effects | Pyrazoles - therapeutic use | Humans | Hemorrhage - prevention & control | Recombinant Proteins - adverse effects | Thiazoles - therapeutic use | Factor VIIa - therapeutic use | Arginine - analogs & derivatives | Dabigatran - therapeutic use | Thiazoles - adverse effects | Pyridines - adverse effects | Rivaroxaban - adverse effects | Factor Xa - therapeutic use | Rivaroxaban - therapeutic use | Factor Xa - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | Piperazines - therapeutic use | Dabigatran - antagonists & inhibitors | Piperazines - adverse effects | Factor Xa Inhibitors - therapeutic use | Hemorrhage - drug therapy | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Blood Coagulation Factors - therapeutic use | Arginine - adverse effects | Pyridones - therapeutic use | Hemorrhage - chemically induced | Hemostatics - therapeutic use | Arginine - therapeutic use | Pyridones - adverse effects
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 10/2009, Volume 6, Issue 10, pp. 596 - 603
...REVIEWS Neurological adverse effects caused by cytotoxic and targeted therapies David Schiff, Patrick Y. Wen and Martin J. van den Bent Abstract | Historically... 
PHASE-II TRIAL | ONCOLOGY | POSTERIOR LEUKOENCEPHALOPATHY SYNDROME | ALBUMIN-BOUND PACLITAXEL | BRAIN-TUMOR CONSORTIUM | ACUTE TRANSIENT ENCEPHALOPATHY | CEREBROSPINAL-FLUID PHARMACOKINETICS | OXALIPLATIN-RELATED NEUROTOXICITY | RECURRENT MALIGNANT GLIOMAS | ANALOG IXABEPILONE BMS-247550 | ADVANCED COLORECTAL-CANCER | Dacarbazine - adverse effects | United States | Humans | Antibodies, Monoclonal - adverse effects | Boronic Acids - adverse effects | Drug Approval | Epothilones - adverse effects | Bevacizumab | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - adverse effects | Dacarbazine - analogs & derivatives | Pyrroles - adverse effects | Angiogenesis Inhibitors - adverse effects | United States Food and Drug Administration | Tubulin Modulators - adverse effects | Bortezomib | Clinical Trials as Topic | Imatinib Mesylate | Piperazines - adverse effects | Neoplasms - drug therapy | Neurotoxicity Syndromes - etiology | Indoles - adverse effects | Pyrazines - adverse effects | Pyrimidines - adverse effects | Benzamides | Antineoplastic Agents, Alkylating - adverse effects | Organoplatinum Compounds - adverse effects | Antimitotic agents | Complications and side effects | Nervous system diseases | Patient outcomes | Dosage and administration | Genetic aspects | Research | Antineoplastic agents | Drug therapy | Risk factors | Cancer | Index Medicus
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 12/2010, Volume 122, Issue 24, pp. 2619 - 2633
proton pump inhibitors | antiplatelet drugs | gastrointestinal hemorrhage | platelet aggregation inhibitors | aspirin | thienopyridine | AHA Scientific Statements | CYTOCHROME-P450 | CARDIAC & CARDIOVASCULAR SYSTEMS | MYOCARDIAL-INFARCTION | ACID SUPPRESSION | PERCUTANEOUS CORONARY INTERVENTION | CLOPIDOGREL | LOW-DOSE ASPIRIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | DISEASE | PERIPHERAL VASCULAR DISEASE | PRASUGREL | PEPTIC-ULCERS | Piperazines - administration & dosage | Prasugrel Hydrochloride | Purinergic P2Y Receptor Antagonists - administration & dosage | Thiophenes - adverse effects | Cardiovascular Diseases - drug therapy | Humans | Thienopyridines - adverse effects | Thienopyridines - metabolism | Piperazines - metabolism | Thiophenes - metabolism | Thiophenes - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - metabolism | Histamine H2 Antagonists - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Aspirin - adverse effects | Aspirin - metabolism | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - metabolism | Ticlopidine - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Platelet Aggregation Inhibitors - metabolism | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Thienopyridines - administration & dosage | Risk Factors | Histamine H2 Antagonists - adverse effects | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Aryl Hydrocarbon Hydroxylases - metabolism | Gastrointestinal Hemorrhage - chemically induced | Gastrointestinal Hemorrhage - prevention & control | Histamine H2 Antagonists - metabolism | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Cytochrome P-450 CYP2C19 | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Proton Pump Inhibitors - metabolism
Journal Article
The American journal of gastroenterology, ISSN 0002-9270, 12/2010, Volume 105, Issue 12, pp. 2533 - 2549
This expert consensus document was developed by the American College of Cardiology Foundation (ACCF), the American College of Gastroenterology (ACG), and the... 
proton pump inhibitors | aspirin | ACCF Expert Consensus Document antiplatelet drugs | gastrointestinal hemorrhage | thienopyridine | platelet aggregation inhibitors | CYTOCHROME-P450 | MYOCARDIAL-INFARCTION | ACID SUPPRESSION | PERCUTANEOUS CORONARY INTERVENTION | CLOPIDOGREL | LOW-DOSE ASPIRIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | DISEASE | PRASUGREL | GASTROENTEROLOGY & HEPATOLOGY | PEPTIC-ULCERS | Piperazines - administration & dosage | Prasugrel Hydrochloride | Purinergic P2Y Receptor Antagonists - administration & dosage | Thiophenes - adverse effects | Cardiovascular Diseases - drug therapy | Humans | Thienopyridines - adverse effects | Thienopyridines - metabolism | Piperazines - metabolism | Thiophenes - metabolism | Thiophenes - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - metabolism | Histamine H2 Antagonists - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Aspirin - adverse effects | Aspirin - metabolism | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - metabolism | Ticlopidine - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Platelet Aggregation Inhibitors - metabolism | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Thienopyridines - administration & dosage | Risk Factors | Histamine H2 Antagonists - adverse effects | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Aryl Hydrocarbon Hydroxylases - metabolism | Gastrointestinal Hemorrhage - chemically induced | Gastrointestinal Hemorrhage - prevention & control | Histamine H2 Antagonists - metabolism | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Cytochrome P-450 CYP2C19 | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Proton Pump Inhibitors - metabolism
Journal Article
Journal of sexual medicine, ISSN 1743-6095, 01/2013, Volume 10, Issue 1, pp. 130 - 171
Erectile dysfunction (ED) is the most frequently treated male sexual dysfunction worldwide. ED is a chronic condition that exerts a negative impact on male... 
Erectile Dysfunction | Phosphodiesterase Inhibitors | Vacuum Device Therapy | Oral Drug Treatment | Combination Therapies | Transurethral Alprostadil Therapy | Intracavernous Self-Injection Therapy | Intracavernous Self‐Injection Therapy | INTRACAVERNOUS ALPROSTADIL ALFADEX | BENIGN PROSTATIC HYPERPLASIA | PHOSPHODIESTERASE TYPE-5 INHIBITOR | URINARY-TRACT SYMPTOMS | ONCE-A-DAY | LONG-TERM SAFETY | UROLOGY & NEPHROLOGY | QUALITY-OF-LIFE | PLACEBO-CONTROLLED TRIAL | VACUUM CONSTRICTION DEVICE | SELF-INJECTION THERAPY | Phosphodiesterase 5 Inhibitors - adverse effects | Humans | Middle Aged | Sulfones - adverse effects | Male | Alprostadil - therapeutic use | Erectile Dysfunction - therapy | Aged, 80 and over | Imidazoles - therapeutic use | Imidazoles - adverse effects | Risk Factors | Phosphodiesterase 5 Inhibitors - administration & dosage | Alprostadil - adverse effects | Yohimbine - adverse effects | Piperazines - therapeutic use | Sulfones - pharmacokinetics | Carbolines - administration & dosage | Piperazines - adverse effects | Sulfonamides - pharmacokinetics | Yohimbine - therapeutic use | Tadalafil | Vardenafil Dihydrochloride | Pyrimidines - pharmacokinetics | Hypogonadism - therapy | Triazines - adverse effects | Sulfonamides - administration & dosage | Sulfones - administration & dosage | Triazines - pharmacokinetics | Piperazines - administration & dosage | Sulfones - therapeutic use | Age Factors | Triazines - therapeutic use | Imidazoles - administration & dosage | Imidazoles - pharmacokinetics | Phosphodiesterase 5 Inhibitors - pharmacokinetics | Alprostadil - administration & dosage | Erectile Dysfunction - drug therapy | Penile Erection - drug effects | Adult | Phosphodiesterase 5 Inhibitors - therapeutic use | Piperazines - pharmacokinetics | Drug Therapy, Combination | Carbolines - therapeutic use | Carbolines - adverse effects | Pyrimidines - administration & dosage | Erectile Dysfunction - etiology | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Triazines - administration & dosage | Hypogonadism - complications | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Carbolines - pharmacokinetics | Hypertension | Care and treatment | Conservatism | Online health care information services | Impotence | Prosthesis | Chronic diseases | Risk factors | Testosterone | Implants, Artificial | Prostaglandins E | Diabetes | Vasoactive intestinal peptides | Special education
Journal Article
Clinical pharmacology and therapeutics, ISSN 1532-6535, 2014, Volume 96, Issue 5, pp. 549 - 558
Journal Article